Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Assessment of COVID-19 progression on day 5 from symptoms onset

Fig. 1

Comparison of laboratory parameters at day-5 from symptoms onset between patents with (red) and without (blue) COVID-19 disease progression. Disease progression is a composite outcome defined as: death and/or transfer to ICU by day-11 after symptom onset, and/or PaO2/FiO2 ratio < 200 on day 10 after symptom onset. CRP C-reactive protein, NLR neutrophils to lymphocytes ratio, LDH lactate dehydrogenase, CK creatine kinase, AST aspartate aminotransferase, ALT alanine transaminase. p-values are reported at the top of each box plot

Back to article page